Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan

被引:14
|
作者
Hsu, Ching-Sheng
Liu, Chun-Jen
Lai, Ming-Yang
Chen, Pei-Jer
Kao, Jia-Horng
Chen, Ding-Shinn
机构
[1] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei 100, Taiwan
[2] Buddhist Tzu Chi Gen Hosp, Dept Hepatogastroenterol, Dept Internal Med, Taipei Branch, Taipei, Taiwan
[3] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Coll Med, Dept Med Res, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Coll Med, Hepatitis Res Ctr, Taipei 10764, Taiwan
[6] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan
关键词
hepatitis C virus; viral kinetics; pegylated interferon; interferon; ribavirin;
D O I
10.1159/000105444
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objectives: Early hepatitis C viral ( HCV) kinetics following pegylated interferon-alpha (PEG-IFN) and ribavirin help to assess treatment in the Western world. Whether this functions in Taiwanese patients remains unknown. Studying the early HCV kinetics in Taiwanese patients may clarify this issue. Methods: Six chronic hepatitis C patients were enrolled. A PEG-IFN-alpha dose was administered at week 1, then it was administered weekly with daily ribavirin for 24 weeks. Serum HCV RNA levels were determined frequently during the trial and qualitatively at week 49. Kinetic parameters epsilon ( effectiveness at inhibiting viral production) and delta ( loss rate of infected cells) were estimated from viral loads and alanine aminotransferase ( ALT) kinetics, respectively. Results: All serum HCV RNA levels became undetectable at week 12. The epsilon ranged from 0.4128 to 0.9904 and delta from 0.0019 to 0.1245. The log values of viral load differences between day 7 and 14 ranged from 0.15 to 1.21. Only 1 patient had an abnormal ALT level at week 49. Conclusions: Viral kinetic parameters in Taiwanese patients were similar to those in Western studies. However, the early viral decline pattern and viral negativity rate in Taiwanese patients might be different from Caucasian patients. Further large-scale studies to clarify this issue are ongoing. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 50 条
  • [21] Efficacy and tolerability of pegylated interferon alpha-2a plus ribavirin versus pegylated interferon alpha-2b plus ribavirin, in treatment naive chronic hepatitis C patients
    Lee, S. Y.
    Lee, S.
    Ko, K. S.
    Kim, I. H.
    Kim, S. H.
    Kim, S. W.
    Lee, S. O.
    Lee, S. T.
    Kim, D. G.
    Choi, C. S.
    Cho, E. Y.
    Kim, H. C.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A176 - A176
  • [22] Hepatitis C Viral Kinetics as a Determinant of Stopping Pegylated Interferon and Ribavirin in Genotype 1 Infection
    Kim, Do Young
    [J]. GUT AND LIVER, 2014, 8 (04) : 335 - 336
  • [23] Pegylated Interferon and Ribavirin Treatment of Chronic Hepatitis C Coinfection in a Patient with Human Immunodeficiency Virus Infection
    Kaptan, Figen
    Turker, Nesrin
    Ormen, Bahar
    El, Sibel
    Hekimoglu, Can Huseyin
    Vardar, Ilknur
    Ural, Serap
    Sener, Asli Gamze
    Coskun, Nejat Ali
    [J]. KLIMIK JOURNAL, 2011, 24 (02) : 122 - 125
  • [24] Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection
    Jessner, W.
    Gschwantler, M.
    Formann, E.
    Gurguta, C.
    Watkins-Riedel, T.
    Ferenci, P.
    [J]. JOURNAL OF HEPATOLOGY, 2008, 48 : S298 - S298
  • [25] Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection
    Jessner, Wolfgang
    Gschwantler, Michael
    Formann, Elisabeth
    Gurguta, Calin
    Watkins-Riedel, Thomas
    Wrba, Friedrich
    Ferenci, Peter
    [J]. ANTIVIRAL THERAPY, 2008, 13 (04) : 581 - 589
  • [26] Comparision of the Side Effects Due To Interferon Alpha 2A Plus Ribavirin and Pegylated Interferon Alpha 2A Plus Ribavirin Combinations For Chronic Hepatitis C Infection
    Ural, Onur
    Demir, Nazlim Aktug
    Sumer, Sua
    Ural, Gaye
    Balci, Mehmet
    [J]. TRAKYA UNIVERSITESI TIP FAKULTESI DERGISI, 2010, 27 (03): : 261 - 264
  • [27] Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin
    Rizzetto, M
    [J]. JOURNAL OF HEPATOLOGY, 2005, 42 (02) : 275 - 276
  • [28] Chronic hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirin
    Fung, James
    Lai, Ching-Lung
    Hung, Ivan
    Young, John
    Cheng, Charles
    Wong, Danny
    Yuen, Man-Fung
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2008, 198 (06): : 808 - 812
  • [29] Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection
    Legrand-Abravanel, F
    Nicot, F
    Boulestin, A
    Sandres-Sauné, K
    Vinel, JP
    Alric, L
    Izopet, J
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2005, 77 (01) : 66 - 69
  • [30] Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection
    Chen, Li-Wei
    Chien, Rong-Nan
    Yen, Cho-Li
    Chang, Jia-Jang
    Liu, Ching-Jung
    Lin, Chih-Lang
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 (02) : 259 - 263